Sprinzl MF, Kirstein MM, Koch S, Seib ML, Weinmann-Menke J, Lang H, Düber C, Toenges G, Zöller D, Marquardt JU, Wörns MA, Galle PR, Vogel A, Pinter M, Weinmann A. Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma Liver Cancer 2019 Oct; 8(5):387-402.
Sprinzl MF, Galle PR. Current progress in immunotherapy of hepatocellular carcinoma. J Hepatol. 2017 Mar; 66(3):482-484.
Wisskirchen K, Metzger K, Schreiber S, Asen T, Weigand L, Dargel C, Witter K, Kieback E, Sprinzl MF, Uckert W, Schiemann M, Busch DH, Krackhardt AM, Protzer U.Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use. PLoS One 2017 Aug 8; 12(8):e0182936.
Sprinzl MF, Puschnik A, Schlitter AM, Schad A, Ackermann K, Esposito I, Lang H, Galle PR, Weinmann A, Heikenwälder M, Protzer U. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. J Hepatol. 2015 Apr; 62(4):863-70.
Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014 Mar 14; 343(6176):1221-8.
Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, Schiemann M, Weinmann A, Galle PR, Schuchmann M, Friess H, Otto G, Heikenwalder M, Protzer U. Sorafenib perpetuates cellular anti-cancer effector functions by modulating the cross talk between macrophages and natural killer cells. Hepatology. 2013 Jun; 57(6):2358-68.
Sprinzl MF, Weinmann A, Lohse N, Tönissen H, Koch S, Schattenberg J, Hoppe-Lotichius M, Zimmermann T, Galle PR, Hansen T, Otto G, Schuchmann M. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. Transpl Int. 2013 Jan; 26(1):67-74.
Kittner JM, Sprinzl MF, Grambihler A, Weinmann A, Schattenberg JM, Galle PR, Schuchmann M. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol. 2012 May; 54(1):93-5.
Kutscher S, Bauer T, Dembek C, Sprinzl M, Protzer U. Design of therapeutic vaccines: hepatitis B as an example. Microb Biotechnol. 2012 Mar;5(2):270-82.
Sprinzl MF, Oberwinkler H, Schaller H, Protzer U. Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier. J Virol. 2001 Jun; 75(11):5108-18.
Buchbeiträge
A. Oberwinkler, M. F. Sprinzl and U. Protzer. Transfer of HBV Genomes into Mice; in: Models of Viral Hepatitis, Eds: F. v. Weizsäcker and M. Roggendorf, Karger Verlag – Basel (2005)
P. R. Galle und M. F. Sprinzl. Kapitel: Infektionskrankheiten der Leber: Akute und chronische Hepatitis, Buchtitel: Gastroenterologie in Klinik und Praxis, 1. Auflage; Hrsg.: J. F. Riemann, W. Fischbach, P.R. Galle, J. Mössner; Georg Thieme Verlag, Stuttgart. (2008) ISBN 978-3-13-141201.
M. F. Sprinzl. Kapitel: Hepatitis B, Hepatitis D, Buchtitel: Referenz Gastroenterologie, 1. Auflage; Hrsg.: J. F. Riemann, W. Fischbach, P.R. Galle, J. Mössner; Georg Thieme Verlag, Stuttgart. (2019) ISBN 978-3-13-240500-4